DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $15 | -81.2% | 1,700 | -77.8% | 0.00% | -85.7% |
Q4 2022 | $80 | -99.8% | 7,650 | +23.4% | 0.01% | +133.3% |
Q3 2022 | $47,000 | +135.0% | 6,200 | +811.8% | 0.00% | +200.0% |
Q2 2022 | $20,000 | -52.4% | 680 | -66.0% | 0.00% | -50.0% |
Q1 2022 | $42,000 | -44.0% | 2,000 | -9.1% | 0.00% | -33.3% |
Q4 2021 | $75,000 | +17.2% | 2,200 | -50.7% | 0.00% | 0.0% |
Q3 2021 | $64,000 | +60.0% | 4,460 | +85.8% | 0.00% | +50.0% |
Q2 2021 | $40,000 | +5.3% | 2,400 | +26.3% | 0.00% | 0.0% |
Q1 2021 | $38,000 | -78.9% | 1,900 | -71.2% | 0.00% | -77.8% |
Q4 2020 | $180,000 | +1900.0% | 6,600 | +214.3% | 0.01% | +800.0% |
Q3 2020 | $9,000 | -73.5% | 2,100 | +45.8% | 0.00% | -50.0% |
Q2 2020 | $34,000 | +6.2% | 1,440 | -44.6% | 0.00% | +100.0% |
Q1 2020 | $32,000 | +300.0% | 2,600 | +420.0% | 0.00% | – |
Q4 2019 | $8,000 | +700.0% | 500 | +400.0% | 0.00% | – |
Q3 2019 | $1,000 | -50.0% | 100 | 0.0% | 0.00% | – |
Q2 2019 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q4 2018 | $2,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |